     Senator Frank R  Lautenberg                                                                                                                      Press Release        of        Senator Lautenberg                                                                                Lautenberg Urges Quick FDA Action on Vaccine to Prevent Cervical Cancer                                                                                                                                                                                                                                                                                                                                           Decision Should be Based on Science  Not Ideology                                                                                                                                                                                                                                                                                                                                                                  Thursday  May 25  2006      WASHINGTON    U S  Senator Frank Lautenberg  D NJ  today urged the Food and Drug Administration to expedite a final decision on a new vaccine that could prevent most cases of cervical cancer  the second most prevalent form of cancer among women       In a letter to FDA Acting Commissioner Dr  Andrew C  von Eschenbach  Lautenberg called on the agency to make a quick ruling on the vaccine Gardasil  which was unanimously recommended for approval last week by the FDA s medical advisory committee  Noting that some people oppose the use of the vaccine for ideological reasons  he urged the FDA to base its decision on science  not politics         The FDA must rule on this vaccine as quickly as possible  because every passing week puts more women at risk for deadly cervical cancer   said Lautenberg   We must put science and women s health ahead of ideological opposition to this vaccine        Gardasil has been proven in clinical trials to prevent transmission of human papilloma virus  HPV   a sexually transmitted disease that causes more than 70 percent of cervical cancers  Cervical cancer kills more than 288 000 women around the world every year  including about 3 700 in the U S       A copy of Senator Lautenberg s letter is attached to this release       May 25  2006      Andrew C  von Eschenbach  M D  Acting Commissioner U S  Food and Drug Administration Food and Drug Administration 5600 Fishers Lane Rockville  Maryland 20857      Dear Dr  von Eschenbach        I was pleased to learn that an advisory panel to the U S  Food and Drug Administration  FDA  unanimously recommended the agency approve Gardasil  a vaccine against the human papilloma virus  HPV   last week  However  some special interest groups with a political and ideological agenda have voiced opposition to its approval  I strongly believe that a decision about such a significant advance in the prevention of cancer  like the HPV vaccine  should be based on scientific facts and free from political interference       HPV is responsible for about 70 percent of all cases of cervical cancer  the number two cancer among women  More than 9 700 U S  women are expected to develop cervical cancer in 2006 and about 3 700 women die from the disease each year  Cervical cancer rates are relatively low in the United States because of widespread use of Pap screening  but globally it is one of the most common cancers in women  Worldwide  the disease kills more than 288 000 women each year  according to the World Health Organization       A successful vaccine could slash that figure by preventing many potentially dangerous HPV infections in the first place  It could also reduce health care costs by cutting down on the number of cancers and pre cancerous conditions that require expensive treatment        In February 2006  the FDA granted priority review for Gardasil  which means the agency has six months from the time of the company s application  December 2005  to make a decision on the vaccine s approval  In light of the upcoming deadline  I urge the F D A  to make a timely decision regarding approval of the HPV vaccine before the six month period ends on June 8th        Thank you for your attention to this matter        Sincerely       Frank R  Lautenberg                     Questions or Comments           